Does glucomannan supplementation exert profitable effects on serum lipid profile in adults? A systematic review and meta-analysis.

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Prostaglandins & other lipid mediators Pub Date : 2024-11-09 DOI:10.1016/j.prostaglandins.2024.106934

Zhu Haijun, Zhang Ke, Zhang Dawei, Amir Reza Haedi, Cheng Cheng, Elika Poorasadollah

{"title":"Does glucomannan supplementation exert profitable effects on serum lipid profile in adults? A systematic review and meta-analysis.","authors":"Zhu Haijun, Zhang Ke, Zhang Dawei, Amir Reza Haedi, Cheng Cheng, Elika Poorasadollah","doi":"10.1016/j.prostaglandins.2024.106934","DOIUrl":null,"url":null,"abstract":"<p><p>Considering dyslipidemia's impact on cardiovascular disease and even chronic illnesses and the beneficial effect of glucomannan on dyslipidemia, this study aimed to examine how glucomannan affects lipid profile parameters thoroughly. Using standard keywords, the databases Scopus, PubMed, Embase, Web of Science databases, and Google Scholar were searched from inception to December 2024. Based on our finding, glucomannan significantly reduced total cholesterol (TC) (SMD: -2.26; 95% CI: -2.98, -1.55, p <0.001), low-density lipoprotein cholesterol (LDL-C) levels (SMD: -2.57; 95% CI: -3.41, -1.74; p<0.001), but not effect on high-density lipoprotein cholesterol (HDL-C) (SMD: -0.33; 95% CI: -0.70, 0.03, p=0.075), and triglyceride (TG) (SMD: -0.16; 95% CI: -0.59, 0.27, p =0.473). However, these significant decreases are not clinically important. Therefore, glucomannan only can be considered as an adjunctive therapeutic approach in managing dyslipidemia.</p>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostaglandins & other lipid mediators","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.prostaglandins.2024.106934","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Considering dyslipidemia's impact on cardiovascular disease and even chronic illnesses and the beneficial effect of glucomannan on dyslipidemia, this study aimed to examine how glucomannan affects lipid profile parameters thoroughly. Using standard keywords, the databases Scopus, PubMed, Embase, Web of Science databases, and Google Scholar were searched from inception to December 2024. Based on our finding, glucomannan significantly reduced total cholesterol (TC) (SMD: -2.26; 95% CI: -2.98, -1.55, p <0.001), low-density lipoprotein cholesterol (LDL-C) levels (SMD: -2.57; 95% CI: -3.41, -1.74; p<0.001), but not effect on high-density lipoprotein cholesterol (HDL-C) (SMD: -0.33; 95% CI: -0.70, 0.03, p=0.075), and triglyceride (TG) (SMD: -0.16; 95% CI: -0.59, 0.27, p =0.473). However, these significant decreases are not clinically important. Therefore, glucomannan only can be considered as an adjunctive therapeutic approach in managing dyslipidemia.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

补充葡萄糖甘露聚糖是否会对成人血清脂质状况产生有利影响？系统回顾和荟萃分析。

考虑到血脂异常对心血管疾病甚至慢性疾病的影响，以及葡甘聚糖对血脂异常的有益作用，本研究旨在深入研究葡甘聚糖如何影响血脂谱参数。本研究使用标准关键词，在 Scopus、PubMed、Embase、Web of Science 数据库和 Google Scholar 等数据库中检索了从开始到 2024 年 12 月的所有研究。研究发现，葡甘聚糖能显著降低总胆固醇（TC）（SMD：-2.26；95% CI：-2.98，-1.55，p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Prostaglandins & other lipid mediators 生物-生化与分子生物学

CiteScore

5.80

自引率

3.40%

发文量

审稿时长

2 months

期刊介绍： Prostaglandins & Other Lipid Mediators is the original and foremost journal dealing with prostaglandins and related lipid mediator substances. It includes basic and clinical studies related to the pharmacology, physiology, pathology and biochemistry of lipid mediators. Prostaglandins & Other Lipid Mediators invites reports of original research, mini-reviews, reviews, and methods articles in the basic and clinical aspects of all areas of lipid mediator research: cell biology, developmental biology, genetics, molecular biology, chemistry, biochemistry, physiology, pharmacology, endocrinology, biology, the medical sciences, and epidemiology. Prostaglandins & Other Lipid Mediators also accepts proposals for special issue topics. The Editors will make every effort to advise authors of the decision on the submitted manuscript within 3-4 weeks of receipt.